(ICCC)

Reporting relationship: VP of Sales and Marketing, Director
Issuer ticker: ICCC
Reported as of: 27 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 Jan 2026, 11:42:02 UTC
Prior SEC filing: 14 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Fiori Attorney-in-Fact

Key filing fact

Bobbi Jo Brockmann filed Form 4 for IMMUCELL CORP /DE/ (ICCC) on 29 Jan 2026.

Key facts

This page summarizes Bobbi Jo Brockmann's Form 4 filing for IMMUCELL CORP /DE/ (ICCC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 29 Jan 2026, 11:42.

Change

Previous filing in this sequence was filed on 14 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001517536 Primary reporting owner

Brockmann Bobbi Jo

Relationship: VP of Sales and Marketing, Director
Address: C/O IMMUCELL CORPORATION, 56 EVERGREEN DRIVE, PORTLAND
Signature: /s/ Timothy C. Fiori Attorney-in-Fact
Signature date: 29 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ICCC transaction Derivative

Stock Options (right to buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 27 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $6.26
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Option grant made to Ms. Brockmann in connection with her employment as Vice President of Sales and Marketing. The option shall be treated as an incentive stock option to the maximum extent permitted by the Internal Revenue Code of 1986, as amended, with the balance treated as a nonqualified stock option. The stock option vests as follows: 33,333 shares becoming exercisable on each of January 27, 2027 and January 27, 2028 and 33,334 shares becoming exercisable on January 27, 2029.